Seikagaku Enters Collaboration on SI-613 in Japan

Seikagaku entered into a basic co-development and marketing collaboration with Ono Pharmaceutical in Japan for SI-613, an injectable hyaluronic acid + NSAID in development for the treatment of osteoarthritis.

The basic agreement is a preliminary step toward signing a definitive...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us